Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) reports consolidated financial results for the fiscal year ended December 31, 2002. The report was issued on February 18, 2003, following a Board of Directors meeting on February 17, 2003. Key corporate developments during the period included the company's listing on the New York Stock Exchange (NYSE) in July 2002 and the acquisition of Pharmacia's 51% interest in Lorex Pharmaceuticals.
Key Financial Metrics
| Metric | 2002 Value | 2001 Value | Change |
|---|---|---|---|
| Consolidated Sales | 7,448 M euros | 6,488 M euros | +14.8% (Reported) |
| Sales Growth (Comparable Basis) | +12.8% | ||
| Gross Margin | 81.5% | 80.7% | +0.8 percentage points |
| Operating Profit | 2,614 M euros | 2,106 M euros | +24.1% |
| Operating Margin | 35.1% | 32.5% | +2.6 percentage points |
| Net Profit (Attributable to Group) | 1,759 M euros | 1,585 M euros | +11.0% |
| Net Profit (Adjusted*) | 1,758 M euros | 1,376 M euros | +27.8% |
| Earnings Per Share (Adjusted*) | 2.42 euros | 1.88 euros | +28.7% |
| R&D Expenses | 1,218 M euros | 1,031 M euros | +18.1% |
| Operating Cash Flow (Pre-Working Capital) | 2,260 M euros | 1,732 M euros | +30.5% |
| Net Cash Position (Dec 31, 2002) | 2,672 M euros | N/A |
*Adjusted figures exclude exceptional items and goodwill amortization.
Material Changes vs. Prior Period
- Sales Growth Drivers: Reported sales growth of 14.8% included a 4.5 percentage point favorable impact from structural changes (e.g., 100% consolidation of Lorex) and a 2.5 percentage point negative impact from currency fluctuations.
- Margin Expansion: Gross margin improved to 81.5% due to a favorable product mix, with the top 15 products rising 28.3%. However, royalties from Plavix and Avapro were reduced due to inventory destocking by partner Bristol Myers-Squibb in the U.S.
- Expense Increases: R&D expenses rose 18.1% to 16.4% of sales, driven by major clinical trials. Selling and general expenses increased 5.3%, though remained stable in the second half of 2002.
- Profitability: Operating profit grew 24.1% (30.1% at constant exchange rates). The U.S. contribution to operating profit increased to 45% from 41% in 2001.
- Cash Flow: While operating cash flow before working capital changes increased significantly, total cash and cash equivalents fell by 1,340 million euros due to a 963 million euro share repurchase program and the 748 million euro acquisition of Lorex.
Outlook, Risks, and Management Commentary
Guidance and Outlook
Management expects 2003 consolidated sales growth on a comparable basis to be similar to 2002 levels. Assuming an exchange rate of 1 euro to 1 dollar, earnings per share (before exceptional items and goodwill amortization) are projected to increase by 20%. Management noted a sensitivity of 1% in the growth rate for every 3-cent movement in the dollar exchange rate.
Dividend Proposal
The Board proposed a dividend of 0.84 euros per share for the 2002 fiscal year, representing a 27.3% increase over the 2001 dividend of 0.66 euros.
Risks and Contingencies
- Clinical Trials: The ANDROMEDA study for dronedarone in congestive heart failure was discontinued in January 2003 due to safety concerns, though pivotal trials for atrial fibrillation (EURIDIS and ADONIS) were recommended to continue.
- Intellectual Property: The company is actively defending Plavix patent rights against generic challenges from Apotex and Dr Reddy Laboratories in the U.S.
- Forward-Looking Risks: Key uncertainties include the ability to expand profitably in the U.S., success of R&D programs, protection of IP rights, and risks related to healthcare reimbursement and pricing reforms in the U.S. and France.
Investor Verification Checklist
- Verify the impact of the discontinued ANDROMEDA study on future R&D spending and pipeline valuation.
- Confirm the status of patent litigation regarding Plavix and the potential impact on future royalty streams.
- Assess the sustainability of the 20% EPS growth guidance given the stated sensitivity to USD/EUR exchange rates.
- Review the details of the share repurchase program cancellation and the resulting treasury share holdings.
- Monitor the integration and performance of the newly acquired Lorex Pharmaceuticals (Ambien) following the 100% consolidation.